Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: a modelling approach

Fig. 2

a Scatter diagram of pem-chemo versus chemo alone. I, pembrolizumab ($1,306.42/100 mg) plus chemotherapy; II, pembrolizumab ($261.28/100 mg) plus chemotherapy; III, chemotherapy alone. b Scatter diagram of atezo-beva-chemo versus chemo alone. I, atezolizumab ($2,377.5/1,200 mg) plus bevacizumab ($131.3/100 mg) plus chemotherapy; II, atezolizumab ($475.5/1200 mg) plus bevacizumab ($26.3/100 mg) plus chemotherapy; III, chemotherapy alone. WTP=$35,424.12

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us